Impact of taxane-based chemotherapy among older women with breast cancer on cognition and quality of life: a longitudinal pooled analysis.

Aged Breast Neoplasms / complications Bridged-Ring Compounds Cognition Female Humans Prospective Studies Quality of Life Taxoids / adverse effects
Breast cancer Chemotherapy Cognition Longitudinal changes Taxanes

Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 21 09 2021
accepted: 14 11 2021
pubmed: 25 11 2021
medline: 20 1 2022
entrez: 24 11 2021
Statut: ppublish

Résumé

Older cancer patients are susceptible to long-term effects of chemotherapy, including cancer-related cognitive decline and impairments to quality of life. Taxane-based chemotherapies are associated with physical declines among older women and may negatively impact cognitive performance. We sought to examine whether changes in objective and subjective measures of cognitive performance and well-being differ among older breast cancer survivors as a function of taxane-based chemotherapy treatment regimens. Individual-level data were pooled and harmonized from two large prospective studies of older (greater than 60 years) breast cancer survivors. Assessments were conducted prior to systemic therapy and up to 36 months after. Cognitive performance was assessed with objective (working memory, processing speed, and executive functions) and subjective tests and physical, emotional, and functional well-being were also assessed. One hundred and sixty-seven (M age = 67.3 years) women with 116 receiving chemotherapy with taxanes and 51 without taxanes contributed data. Declines in subjective cognition for both groups were significant between pre-treatment and 12-month follow-up. Significant improvements were seen on a measure of objective cognition (working memory) from 12 to 36 months. Measures of well-being improved from prior to systemic therapy to 12 months. Longitudinal changes across all measures did not vary as a function of receipt of taxane-based treatment. Older women who received treatment with taxanes did not have greater declines in cognitive performance or well-being than women receiving other chemotherapy regimens. Despite older cancer survivors being at greater risk for negative outcomes, treatment with taxane-based chemotherapies does not appear to exacerbate these health consequences.

Identifiants

DOI: 10.1007/s10549-021-06455-6 PMID: 34817750 PMC: PMC8766903
pubmed: 34817750
doi: 10.1007/s10549-021-06455-6
pii: 10.1007/s10549-021-06455-6
pmc: PMC8766903
mid: NIHMS1759818
doi:

Substances chimiques

Bridged-Ring Compounds 0
Taxoids 0
taxane 1605-68-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

459-469

Subventions

Organisme : NIA NIH HHS
ID : R01AG068193
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG019771
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA237535
Pays : United States
Organisme : NIA NIH HHS
ID : P30AG10133
Pays : United States
Organisme : NCI NIH HHS
ID : R35CA197289
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA244673
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA237535
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA129769
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA129769
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG072976
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA244673
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197289
Pays : United States
Organisme : EPA
ID : EP-D-17-023
Pays : United States
Organisme : NIA NIH HHS
ID : R01AG19771
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA137788
Pays : United States
Organisme : EPA
ID : EP-C-17-023
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA172119
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010133
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA172119
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA241337
Pays : United States
Organisme : NIA NIH HHS
ID : P30AG028716
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA132378
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG068193
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG028716
Pays : United States
Organisme : NIA NIH HHS
ID : R33 AG059206
Pays : United States
Organisme : NCI NIH HHS
ID : K08CA241337
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Psychol Methods. 2009 Jun;14(2):126-49
pubmed: 19485625
JNCI Cancer Spectr. 2019 Jun 07;3(3):pkz041
pubmed: 31355357
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
J Clin Oncol. 2018 Oct 3;:JCO1800140
pubmed: 30281396
Eur J Cancer. 2014 Sep;50(13):2181-9
pubmed: 24958735
J Clin Oncol. 2020 Jun 10;38(17):1875-1886
pubmed: 32271671
J Gerontol A Biol Sci Med Sci. 2019 Oct 4;74(11):1793-1804
pubmed: 30825374
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S63-86
pubmed: 26402085
J Clin Oncol. 2017 Feb 10;35(5):506-514
pubmed: 28029304
J Clin Oncol. 2014 Jun 20;32(18):1909-18
pubmed: 24841981
J Am Geriatr Soc. 1992 Sep;40(9):922-35
pubmed: 1512391
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36
pubmed: 27371756
JAMA. 2018 Jan 9;319(2):154-164
pubmed: 29318276
CA Cancer J Clin. 2015 Mar;65(2):123-38
pubmed: 25483452
J Clin Oncol. 2016 Jul 10;34(20):2416-27
pubmed: 27091714
Br J Pharmacol. 2020 Jul;177(14):3127-3146
pubmed: 32352155
Breast Cancer Res Treat. 2017 Jul;164(1):179-187
pubmed: 28421379
J Clin Oncol. 2012 Oct 20;30(30):3675-86
pubmed: 23008308
Support Care Cancer. 2011 Oct;19(10):1647-56
pubmed: 20820813
J Clin Oncol. 2010 Oct 10;28(29):4434-40
pubmed: 20837957
Neuroepidemiology. 2014;43(3-4):194-205
pubmed: 25402421
J Am Geriatr Soc. 2019 May;67(5):920-927
pubmed: 30146695
J Clin Oncol. 2016 Sep 1;34(25):3014-22
pubmed: 27325863
J Clin Oncol. 2014 Aug 20;32(24):2662-8
pubmed: 25071099
J Clin Oncol. 1997 Mar;15(3):974-86
pubmed: 9060536
Psychooncology. 2020 Jun;29(6):1051-1059
pubmed: 32154959
Support Care Cancer. 2015 Nov;23(11):3219-28
pubmed: 25832894
Support Care Cancer. 2012 Dec;20(12):3297-305
pubmed: 22549504
Cancer Treat Rev. 2014 Jul;40(6):810-7
pubmed: 24713425
Psychooncology. 2014 Dec;23(12):1382-90
pubmed: 24789331
Cancer. 2020 Mar 15;126(6):1183-1192
pubmed: 31860135
Oncologist. 2016 Nov;21(11):1337-1348
pubmed: 27473044

Auteurs

Brent J Small (BJ)

School of Aging Studies, University of South Florida, 13301 Bruce B. Downs Blvd, Tampa, FL, 33620, USA. bsmall@usf.edu.
ORCID: 0000-0002-7444-4689

Marie Lange (M)

Medical Oncology Department, Centre François Baclesse, and Normandie University, UNICAEN, INSERM, ANTICIPE, and Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, Caen, France.

Wanting Zhai (W)

Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

Jaeil Ahn (J)

Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

Tim A Ahles (TA)

Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Judith E Carroll (JE)

UCLA Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center and Cousins Center for Psychoneuroimmunology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.

Harvey J Cohen (HJ)

Center for the Study of Aging and Human Development, Duke University School of Medicine, Durham, NC, USA.

Deena Graham (D)

John Theurer Cancer Center, Hackensack, NJ, USA.

Martine Extermann (M)

Department of Oncology Sciences, Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL, USA.

Natacha Heutte (N)

Department of Clinical Research, Center François Baclesse, and Normandie Université, Caen, France.

Heather S L Jim (HSL)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.

Brenna C McDonald (BC)

Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine and the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.

Sunita K Patel (SK)

Departments of Population Sciences and Supportive Care Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

James C Root (JC)

Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Andrew J Saykin (AJ)

Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine and the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.

Kathleen Van Dyk (K)

Department of Psychiatry and Biobehavioral Sciences David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Semel Institute, Los Angeles, CA, USA.

Xingtao Zhou (X)

Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

Jeanne Mandelblatt (J)

Department of Oncology, Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

Florence Joly (F)

Medical Oncology Department, Centre François Baclesse, and Normandie University, UNICAEN, INSERM, ANTICIPE, and Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Impact of taxane-based chemotherapy among...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Impact of taxane-based chemotherapy among...
questionsmedicales.fr › Composés polycycliques › Composés pontés › Impact of taxane-based chemotherapy among...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Cognition › Impact of taxane-based chemotherapy among...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Impact of taxane-based chemotherapy among...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Impact of taxane-based chemotherapy among...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Impact of taxane-based chemotherapy among...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › Taxoïdes › Impact of taxane-based chemotherapy among...